Pernix Therapeutics (PTX) Reports Q3 Loss of $2.99/Share

November 10, 2016 4:04 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($2.99), versus ($1.76) reported last year. Revenue for the quarter came in at $41.5 million, versus $48.6 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment